

Appl. No. 09/529,575
 Docket No. 7042RL+
 Amdt. dated June 28, 2007
 Reply to Office Action mailed on April 2, 2007
 Customer No. 27752

RECEIVED
 CENTRAL FAX CENTER
JUN 28 2007

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1-30. (Canceled)
- 31. (Currently amended) A disposable wearable article comprising a liquid pervious topsheet, a liquid impervious backsheet and an absorbent core positioned between the topsheet and the backsheet, wherein the topsheet that comprises a protease inhibitor, wherein the topsheet of the article comprises and a delivery system for releasably containing and delivering from about 0.0001% to about 30%, by weight, of the protease inhibitor to at least a portion of the skin of a wearer of the article, wherein the delivery system releases the protease inhibitor when activated and wherein the delivery system is activatable by moisture, heat, or pressure, or combination thereof; the protease inhibitor has an IC₅₀ of about 500 μM or less, as measured by a General Fecal Protease Method; the protease inhibitor is selected from the group consisting of 4-(2-aminoethyl)-benzenesulfonylfluoride hydrochloride, hexamidine and its salts, pentamidine and its salts, and mixtures thereof; and wherein an extract of at least a portion of the article produces at least a 10% reduction in substrate hydrolysis by a protease in an Absorbent Article Test Method.
- 32. (Original) The article of claim 31 wherein the IC₅₀ is no more than 100 μM.
- 33-35. (Canceled)
- 36. (Previously Presented) The article of claim 31 wherein the extract of at least a portion of the absorbent article produces a 20% reduction in substrate hydrolysis by a protease in an Absorbent Article Test Method.
- 37-40. (Canceled)
- 41. (Canceled)

Appl. No. 09/529,575
Docket No. 7042RL+
Amdt. dated June 28, 2007
Reply to Office Action mailed on April 2, 2007
Customer No. 27752

42. (Previously Presented) The article of claim 31, wherein the delivery system is in the form of a skin care composition and the skin care composition comprises from about 0.01% to about 50%, by weight, of the protease inhibitor.
43. (Original) The article of claim 42, wherein the skin care composition is transferable to the skin of a wearer.
44. (Previously Presented) The article of claim 31, wherein the delivery system comprises a microcapsule, an absorbent material, a cell, an adhesive, a skin care composition, a nanophase particulate structure, a solid support, or combinations thereof.
45. (Canceled)
46. (Previously Presented) The article of claim 31, wherein the delivery system contains the protease inhibitor as a powder, a flake, a particle, a solution, a suspension, a dispersion, an emulsion, or combination thereof.
47. (Canceled)
48. (Previously Presented) The article of claim 31, wherein the topsheet comprises a wearer-contacting surface having the protease inhibitor disposed on at least a portion thereof.
- 49-51. (Canceled)
52. (Previously Presented) The article of claim 31, wherein the topsheet comprises one or more regions that do not contain the skin care composition.
53. (Previously Presented) The article of claim 31, wherein the skin care composition is disposed on the topsheet in a plurality of stripes.